SCHEMBL4476247

SCHEMBL4476247

COc1cc2c(Oc3ccc(Nc4ccc(C(C)(C)C)cc4)cc3)ccnc2cc1OCCCN1CCOCC1

nearest known ligand 0.92

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR2 P21802 9/20 0.92
KDR P35968 3/20 0.65
PDGFRB P09619 1/20 0.65
KIT P10721 1/20 0.65
PDGFRA P16234 1/20 0.65
MET P08581 4/20 0.65
SRC P12931 1/20 0.62
AURKA O14965 1/20 0.60
RPS6KA5 O75582 1/20 0.60
LCK P06239 1/20 0.60
PIM1 P11309 1/20 0.60
HGF P14210 1/20 0.60
RPS6KB1 P23443 1/20 0.60
MAPK9 P45984 1/20 0.60
TEK Q02763 1/20 0.60
MST1R Q04912 1/20 0.60
BTK Q06187 1/20 0.60
MAP2K1 Q02750 3/20 0.59
AXL P30530 1/20 0.59
RAF1 P04049 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4465059 0.98 FGFR2 (0.91) FGFR2KDRPDGFRBKITPDGFRA
SCHEMBL4485078 0.96 FGFR2 (1.00) FGFR2KDRPDGFRBKITPDGFRA
SCHEMBL4478724 0.96 FGFR2 (1.00) FGFR2KDRPDGFRBKITPDGFRA
SCHEMBL4479490 0.93 FGFR2 (0.98) FGFR2KDRPDGFRBKITPDGFRA
SCHEMBL4471592 0.92 FGFR2 (1.00) FGFR2KDRPDGFRBKITPDGFRA
SCHEMBL4478491 0.92 FGFR2 (1.00) FGFR2KDRPDGFRBKITPDGFRA
SCHEMBL4473146 0.92 FGFR2 (0.87) FGFR2KDRPDGFRBKITPDGFRA
SCHEMBL4487243 0.89 FGFR2 (0.95) FGFR2KDRPDGFRBKITPDGFRA
SCHEMBL4484976 0.89 FGFR2 (0.83) FGFR2KDRPDGFRBKITPDGFRA
SCHEMBL4464922 0.89 FGFR2 (0.82) FGFR2KDRPDGFRBKITPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US claimed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2005-03-03 US disclosed
EP-1447405-A1 QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS KIRIN BEER KABUSHIKI KAISHA (JP) 2004-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors FGFR1, FGFR2, FGFR3 FGFR2 2/4885KDR 211/4885PDGFRB 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.